Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Allergic rhinitis (Fluticasone with azelastine - Allergic rhinitis)

Records returned : 31 (on 29 May 2025 at 12:58:48). Return to search results for ' Allergic rhinitis '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
1.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important
Reserved for use where monotherapy is inadequate. Not 1st line.
 
Links :
Indication :
Status :
Green
Formulations :
  • Nasal spray
Restrictions / Comments:

Important

Recommended as an alternative where an intranasal antihistamine is indicated

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

Prescribe generically.

Available to buy over the counter.

Exceptions may apply see Guidelines on PAD

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Oral solution
Restrictions / Comments:

Important

Loratadine 5mg/5ml sugar free oral solution (from 2 years) is the 1st-line option. Cetirizine liquid is considerably more expensive and is a 2nd line option for patients unable to swallow tablets.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Capsules
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Prescribe generically.

Available to purchase over the counter .

Exceptions may apply see Guidelines on PAD

 
Links :
Indication :
Status :
Green
Formulations :
  • Nasal spray
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

Prescribe generically.

Available to buy over the counter.

Exceptions may apply see Guidelines on PAD

 
Links :
Indication :
Status :
Green
Formulations :
  • Oral solution
Restrictions / Comments:

Important
Preferred

Loratadine 5mg/5ml oral solution sugar free is the preferred option in patients unable to swallow tablets.Available to buy over the counter.

Exceptions may apply see Guidelines on PAD

 
Links :
Indication :
Status :
Green
Formulations :
  • Nasal spray
Restrictions / Comments:

Important
Preferred

Recommended 1st line treatment option

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important

Beclometasone 50mcg/dose (200 dose container) is recommended as a 1st line alternative treatment option. NOTE Beconase Hayfever and other container sizes (180 dose and 100 dose) are much more expensive and should not be used.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important

Mometasone Furoate 50mcg/dose 140 dose container is the recommended 1st line treatment option. Budesonide is recommended as a 2nd line option

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Not a 1st-line option. Use cetirizine or loratadine 1st line.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Oral solution
Restrictions / Comments:

Important
Loratadine liquid is 1st line in patients unable to swallow tablets (from 2 years of age)
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
2nd line to loratadine / cetirizine tablets. 120mg tablets available to buy over the counter.180mg tablets NOT licensed for allergic rhinitis. 30mg reserved for paediatrics.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important

Mometasone Furoate is the preferred intranasal steroid for allergic rhinitis. If fluticasone is required, prescribe as fluticasone furoate in Primary Care (less costly option). Prices may vary in secondary care. NOTE: ASPH restrict fluticasone furoate to use in paediatrics due to smaller nozzle size.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important

Mometasone Furoate is the preferred intranasal steroid for allergic rhinitis. If fluticasone is required, prescribe as fluticasone furoate in Primary Care (less costly option). Prices may vary in secondary care. NOTE: ASPH recommend fluticasone furoate in paediatrics due to smaller nozzle size.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Not a 1st-line option. Use cetirizine or loratadine 1st-line.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Oral solution
Restrictions / Comments:

Important
Loratadine liquid is 1st line in patients unable to swallow tablets (from 2 years of age).
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important
Reserved for use where monotherapy is inadequate. Not 1st line.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Nasal spray
Restrictions / Comments:

Important

Mometasone Furoate 50mcg/dose (140 dose container) is the preferred intranasal steroid for allergic rhinitis. Triamcinolone is considered to be a 3rd / 4th line agent.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Capsules
  • Elixir
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Discontinued April 2024. Refer to guidelines for alternatives.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Oral solution
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

Important

This product, for this indication, has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.

 
Links :